Dr. Brian L. Mcclune, DO
Hematology & Oncology (Hematology & Oncology Physician)
1950 Circle Of Hope Dr
Salt Lake City, UT 84112
Who else practices at this address →
Salt Lake County includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Kansas City College of Medicine and Surgery (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 148
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Kansas City College of Medicine and Surgery
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
UT license 11448582-1204
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Utah Hospital and Clinics Salt Lake City, UT
- Memorial Hospital Sweetwater County Rock Springs, WY
Medical groups
- University of Utah Adult Services (1,788 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 148
- Services billed
- 1,531
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 256 | 19 |
| Established patient office or other outpatient visit, 40-54 minutes | 224 | 99 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 92 | 18 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 33 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Revlimid (lenalidomide) | 169 |
| Acyclovir Other prescribers in Salt Lake City, UT | 126 |
| Omeprazole Other prescribers in Salt Lake City, UT | 58 |
| Dexamethasone Other prescribers in Salt Lake City, UT | 49 |
| Pomalyst (pomalidomide) | 42 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Salt Lake City, UT | 38 |
| Eliquis (apixaban) Other prescribers in Salt Lake City, UT | 33 |
| Potassium Chloride Other prescribers in Salt Lake City, UT | 27 |
| Xarelto (rivaroxaban) Other prescribers in Salt Lake City, UT | 26 |
| Gabapentin Other prescribers in Salt Lake City, UT | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 6 payments worth $1,812 in total to this clinician.
| National Marrow Donor Program | $994 |
|---|---|
| Daiichi Sankyo Inc. | $650 |
| Incyte Corporation | $125 |
| AstraZeneca Pharmaceuticals LP | $43.25 |
| Travel and Lodging | $891 |
|---|---|
| Consulting Fee | $650 |
| Food and Beverage | $227 |
| Education | $43.25 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Sep 22, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| National Marrow Donor Program Jun 12, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN · in-kind | $588 |
| National Marrow Donor Program Jun 13, 2025 | Travel and Lodging travel to MINNEAPOLIS, MN · in-kind | $303 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $43.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $473,456 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma
Janssen Research & Development, LLC - A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants Wi…
E.r. Squibb & Sons, L.l.c. - A phase 2 open-label, multicenter study evaluating the safety and efficacy of axicabtagene-ciloleucel concomitant with prophylactic steroids in subjects with relapsed or refractory large b-cell lymphoma in the outpati…
Kite Pharma, Inc. - A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Celgene Corporation · Active, not recruiting · NCT02773030 - Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Kite Pharma, Inc. - Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel
Kite Pharma, Inc. - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
E.r. Squibb & Sons, L.l.c. - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.